核转录因子狈贵-κ叠受体/核因子办叠受体活化因子抗体
规格：1尘驳/1尘濒
英文名： RANK
别名： TNFRSF11A; CD 265; CD265; CD265 antigen; Activator of NFKB; EOF; FEO; mRANK; NFKB activator; ODFR; OFE; Osteoclast differentiation factor receptor; PDB 2; Receptor activator of NF KB; receptor activat
分子量： 63kDa
储存液：0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glyce
克隆类型：笔辞濒测肠濒辞苍补濒
亚型：滨驳骋
纯化方法：affinity purified by Protein A
**原：KLH conjugated synthetic peptide derived from human RANK/CD2
交叉反应：Human, Mouse, Rabbit, Sheep,
细胞定位：细胞膜
核转录因子狈贵-κ叠受体/核因子办叠受体活化因子抗体产物介绍：background: CD265 is a member of the tumor necrosis factor receptor (TNFR) family. Human and murine CD265 share 81% amino acid identity in their extracellular domains. CD265 is widely expressed, with highest levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland. CD265 is also expressed in dendritic cells. RANK and RANK ligand (RANKL) are important regulators of interactions between T cells and dendritic cells. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Multiple tumor necrosis factor receptor-associated factors (TRAFs) are involved in the signaling of CD265. TRANCE (TNF-related activation-induced cytokines, also known as RANK ligand, osteoprotegerin ligand and osteoclast differentiation factor) is the ligand for CD265. The biological functions mediated by RANK include activation of NFkappaB and cjun N-terminal kinase, enhancement of T cell growth and dendritic cell function, induction of osteoclastogenesis and lymph node organogenesis. The soluble form of CD265 is able to block TRANCE induced biological activity. The binding of anti-CD265 to cell surface CD265 triggers signal transduction and induces CD265 mediated bioactivity. Function: Receptor for 核转录因子狈贵-κ叠受体/核因子办叠受体活化因子抗体TNFSF11/RANKL/TRANCE/OPGL; essential for RANKL-mediated osteoclastogenesis. Involved in the regulation of interactions between T-cells and dendritic cells. Subcellular Location: Membrane. Tissue Specificity: Ubiquitous expression with high levels in skeletal muscle, thymus, liver, colon, small intestine and adrenal gland. DISEASE: Defects in TNFRSF11A are the cause of familial expansile osteolysis (FEO) [MIM:174810]. FEO is a rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early hood. FEO is often associated with early onset deafness and loss of dentition. Defects in TNFRSF11A are a cause of Paget disease of bone type 2 (PDB2) [MIM:602080]; also known as familial Paget disease of bone. PDB2 is a bone-remodeling disorder核转录因子狈贵-κ叠受体/核因子办叠受体活化因子抗体 with clinical similarities to FEO. Unlike FEO, however, affected individuals have involvement of the axial skeleton with lesions in the spine, pelvis and skull. Similarity: Contains 4 TNFR-Cys repeats. Gene ID: 8792 Database links: Entrez Gene: 8792 Human Entrez Gene: 21934 Mouse Omim: 603499 Human SwissProt: Q9Y6Q6 Human SwissProt: O35305 Mouse Unigene: 204044 Human Unigene: 6251 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
产核转录因子狈贵-κ叠受体/核因子办叠受体活化因子抗体品应用：WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user.
研究领域：肿瘤 细胞生物 转录调节因子 细胞表面分子
储存条件：
来源： Rabbit
外观： Lyophilized or Liquid